Combination of bleomycin, etoposide and cisplatin (BEP) versus etoposide and cisplatin (EP) in patients with good risk nonseminomatous germ cell tumors (NSGCT)

被引：0
|
作者：
Tryakin, A. [1 ]
Fedyanin, M. [1 ]
Bulanov, A. [1 ]
Titov, D. [1 ]
Mitin, A. [2 ]
Sergeev, J. [3 ]
Figurin, K. [2 ]
Fainstein, I. [3 ]
Matveev, V. [2 ]
Zakharova, T. [4 ]
Kostjakova, L. [5 ]
Garin, A. [1 ]
Tjulandin, S. [1 ]
机构：
[1] NN Blokhin Russian Canc Res Ctr, Clin Pharmacol & Chemotherapy, Moscow, Russia
[2] NN Blokhin Russian Canc Res Ctr, Urol, Moscow, Russia
[3] NN Blokhin Russian Canc Res Ctr, Radiosurg, Moscow, Russia
[4] NN Blokhin Russian Canc Res Ctr, Pathomorphol, Moscow, Russia
[5] NN Blokhin Russian Canc Res Ctr, Radiol, Moscow, Russia
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31428-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2610
引用
收藏
页码：S515 / S515
页数：1
相关论文
共 50 条
  • [1] Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
    McHugh, Deaglan Joseph
    Funt, Samuel
    Silber, Deborah
    Knezevic, Andrea
    Patil, Sujata
    O'Donnell, Devon
    Tsai, Stephanie
    Reuter, Victor E.
    Sheinfeld, Joel
    Carver, Brett Stewart
    Motzer, Robert J.
    Bajorin, Dean F.
    Bosl, George J.
    Feldman, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [2] Cisplatin, etoposide and bleomycin infusion (PEBi regimen) in good-risk patients with germ cell tumors
    Colleoni, M
    Graffeo, R
    Martinelli, G
    Ghielmini, M
    DeBraud, P
    Zampino, G
    Marini, G
    Cavalli, F
    Goldhirsch, A
    ONCOLOGY REPORTS, 1997, 4 (05) : 913 - 916
  • [3] Cisplatin, etoposide and bleomycin infusion (PEBi regimen) in good-risk patients with germ cell tumors
    Colleoni, M
    Graffeo, R
    Martinelli, G
    Ghielmini, M
    Marini, G
    Cavalli, F
    Goldhirsch, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 176 - 176
  • [4] Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    McHugh, Deaglan Joseph
    Funt, Samuel
    Silber, Deborah
    Knezevic, Andrea
    Patil, Sujata
    O'Donnell, Devon
    Tsai, Stephanie
    Reuter, Victor E.
    Sheinfeld, Joel
    Carver, Brett Stewart
    Motzer, Robert J.
    Bajorin, Dean F.
    Bosl, George J.
    Feldman, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] THE TREATMENT OF METASTATIC GERM-CELL TESTICULAR-TUMORS WITH BLEOMYCIN, ETOPOSIDE AND CISPLATIN (BEP)
    PECKHAM, MJ
    BARRETT, A
    LIEW, KH
    HORWICH, A
    ROBINSON, B
    DOBBS, HJ
    MCELWAIN, TJ
    HENDRY, WF
    BRITISH JOURNAL OF CANCER, 1983, 47 (05) : 613 - 619
  • [6] Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: Is there a preferred regimen?
    Einhorn, LH
    Foster, RS
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2597 - 2598
  • [7] Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II)) vinblastine, bleomycin (VBIV) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors
    Culine, S
    Theodore, C
    Bekradda, M
    Farhat, F
    TerrierLacombe, MJ
    Droz, JP
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (02): : 184 - 188
  • [8] SEQUENTIAL TRIALS OF CISPLATIN, VINBLASTINE, AND BLEOMYCIN AND ETOPOSIDE AND CISPLATIN IN DISSEMINATED NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS WITH A GOOD PROGNOSIS AT A SINGLE INSTITUTION
    GERMA, JR
    SAGARRA, AF
    IZQUIERDO, MA
    SEGUI, MA
    CANCER, 1993, 71 (03) : 796 - 803
  • [9] Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: Is there a preferred regimen? Reply
    Kondagunta, GV
    Motzer, RJ
    Bosl, GJ
    Sheinfeld, J
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2598 - 2599
  • [10] A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors
    Bokemeyer, C
    Kohrmann, O
    Tischler, J
    Weissbach, L
    Rath, U
    Haupt, A
    Schoffski, P
    Harstrick, A
    Schmoll, HJ
    ANNALS OF ONCOLOGY, 1996, 7 (10) : 1015 - 1021
12345